Atlas.
Sign inStart free trial
KYMRNASDAQ · US

Kymera Therapeutics, Inc.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Nello Mainolfi
Founded
—
IPO Date
—
HQ
Watertown, MA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$114.20 ▲ 57.0%
Last (1 Jul 2026) · $114
Period High · $116.46
Period Low · $0.00
52W: $114.20 – $116.46

Key Metrics

Share Price
$114.20
-0.4% today
Market Cap
$8.2B
P / E
—
EV / Revenue
200.4x
Revenue Growth
-16.7%
year-on-year
Gross Margin
—
Enterprise Value
$7.9B
52W High
$116.46
52W Low
$0.00
Avg Volume
736K
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
12 known institutional holders·$2.1B total on record·2026-Q1
Fmr LLC
16.3%·$974M
Price T Rowe Associates Inc
8.4%·$504,809
BlackRock, Inc.
7.0%·$422M
State Street Corp
3.3%·$199M
Capital Research Global Investors
2.3%·$139M
Geode Capital Management, LLC
2.3%·$137M
Goldman Sachs Group Inc
1.2%·$74M
Dimensional Fund Advisors LP
0.8%·$49M
Northern Trust Corp
0.7%·$41M
Bank Of America Corp
0.4%·$24M
Jpmorgan Chase & Co
0.2%·$10M
Invesco Ltd.
0.2%·$9M
Free Float
56.9%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Kymera Therapeutics, Inc.
OverviewKymera Therapeutics, Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Kymera Therapeutics, Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsKymera Therapeutics, Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityKymera Therapeutics, Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsKymera Therapeutics, Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Kymera Therapeutics, Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Kymera Therapeutics, Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersKymera Therapeutics, Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Kymera Therapeutics, Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Kymera Therapeutics, Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial